Fundz

INNOVATE Corp

New York, New York, United States

Pansend Life Sciences is INNOVATE’s life sciences platform. Founded by Cherine Plumaker and David Present in 2014, Pansend has a dynamic management team. Pansend’s sale of BeneVir to Janssen Biotech for up to $1 billion in 2018 demonstrates its ability to develop and monetize assets. BeneVir’s proprietary T-Stealth oncolytic virus platform develops viruses used to infect and destroy cancer cel

Key facts

Headquarters
New York, New York, United States
Employees
Unknown
Status
Public (VATE)
Website
innovatecorp.com
LinkedIn
Company page

Recent activity at INNOVATE Corp

  • : SEC 8-K (8.01): On November 13, 2026, INNOVATE Corp. filed a prospectus supplement to its effective shelf registration statement, increasing the aggregate offering amount of shares from $31 million to $50 million in connection with its at-the-market sales program. The new prospectus supplement replaces the prior one and is related to an agreement with Jefferies LLC. Additionally, a legal opinion from Cleary Gottlieb Steen & Hamilton LLP was filed, confirming the validity of the newly registered shares. This proactive step indicates the company's strategy to enhance liquidity and capital raising capabilities in the current market conditions.
  • : SEC 8-K (7.01): The Company has announced a Regulation FD disclosure regarding a conference call scheduled for today, November 12, 2026, at 4:30 p.m. ET. During this call, management will discuss the company's performance, and presentation slides will be made available on the Company's Investor Relations webpage prior to the event. This call will be webcast simultaneously, thereby allowing broader access to stakeholders. The information is not considered 'filed' under the Securities Exchange Act and is intended for discussion purposes only.
  • : SEC 8-K (1.01): Innovate Corp. has entered into a supplemental indenture regarding its 9.500% Convertible Senior Secured Notes due 2027. This supplemental indenture amends the existing indenture, which was established on August 4, 2025, and mandates the redemption of all Convertible Notes on the 15th business day following the end of the lock-up period related to stock consideration from the previously announced sale of DBMG Global Inc. The DBMG Sale indicates a strategic adjustment in the company’s capital structure and liquidity management, reflecting an important step in their ongoing business operations. This agreement is significant for the management of outstanding debt and will impact the company’s financial obligations moving forward.
  • : SEC 8-K (1.01): On October 5, 2026, Innovate Corp. entered into a material definitive agreement by completing the sale of DBMG Global, Inc., which is part of a larger restructuring strategy. This transaction included the repayment of all outstanding obligations under the company's revolving credit agreement with MSD PCOF Partners, effectively concluding prior commitments and facilitating future financial flexibility. The transaction was instrumental in shifting the company's focus towards growth initiatives, thereby strengthening its balance sheet and investor confidence.
  • : SEC 8-K (1.01):
  • : SEC 8-K (8.01): On August 18, 2026, Innovate Corp. announced through a press release that its MediBeacon ® Transdermal GFR System has been nominated for the 2026 Prix Galien USA Best Medical Technology award. This nomination signifies recognition within the medical technology field and may enhance the company's reputation and market position. The press release sheds light on Innovate Corp.'s innovative advancements in medical technology. The event underscored the company's commitment to pioneering health solutions and hints at potential growth in interest or investment following such recognition.
  • : SEC 8-K (1.01): On August 7, 2026, INNOVATE Corp. entered into a Transaction Agreement with IES Holdings, Inc., IES Merger Sub, Inc., and DBM Global Intermediate Holdco Inc. to sell approximately 91.21% of DBM Global, Inc.'s shares for a total consideration of $650 million. This agreement includes the sale of shares and a merger, with expected closure in Q4 2026. The financial structuring includes stock consideration in the form of 215,487 shares of the buyer's stock and about $453 million in cash, subject to customary adjustments. Additional cash compensation of $35 million is also agreed upon for tax-related costs associated with the transaction.
  • : SEC 8-K (7.01): The Company, INNOVATE Corp., has filed a Regulation FD Disclosure reporting a conference call scheduled for today, August 6, 2026, at 4:30 p.m. ET. The call will include a presentation which will be available on the Company's Investor Relations website prior to its commencement. This conference call allows for the disclosure of significant information to all investors simultaneously, enhancing transparency and compliance with SEC regulations regarding fair disclosure. The press release accompanying the call details the insights on the second quarter performance of 2026.
  • : SEC 8-K (1.01): On July 31, 2026, INNOVATE Corp. and certain subsidiary guarantors entered into two supplemental indentures with U.S. Bank Trust Company, allowing interest on specific Senior Secured Notes to be paid in kind. Notably, the principal for the 10.500% Senior Secured Notes will rise to $400.9 million, with cash interest payment reduced to $3.1 million. Additionally, R2 Technologies, in which INNOVATE has a controlling interest, amended a Senior Secured Promissory Note with Lancer Capital, extending the maturity date. This financial maneuver benefits consenting holders while maintaining the interest terms for non-consenting holders.
  • : SEC 8-K (8.01): On July 8, 2026, INNOVATE Corp. issued a press release announcing that its portfolio company, DBM Global, will pay a cash dividend. This decision reflects the company's commitment to return value to its shareholders. The cash dividend details and implications for the company's financial strategy were outlined in the press release, which is attached as Exhibit 99.1. This event is significant as it underlines the financial health of the portfolio company and its ability to distribute profits to shareholders.

Leadership

  • Suzi Herbst, Chief Operating Officer

Verified email and direct lines for INNOVATE Corp’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

INNOVATE Corp files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

INNOVATE Corp in the news

About INNOVATE Corp: questions and answers

What does INNOVATE Corp do?

Pansend Life Sciences is INNOVATE’s life sciences platform. Founded by Cherine Plumaker and David Present in 2014, Pansend has a dynamic management team. Pansend’s sale of BeneVir to Janssen Biotech for up to $1 billion in 2018 demonstrates its ability to develop and monetize assets. BeneVir’s proprietary T-Stealth oncolytic virus platform develops viruses used to infect and destroy cancer cel

Where is INNOVATE Corp headquartered?

INNOVATE Corp is headquartered in New York, New York, United States.

What is the latest news on INNOVATE Corp?

On Nov 13, 2026, SEC 8-K (8.01): On November 13, 2026, INNOVATE Corp. filed a prospectus supplement to its effective shelf registration statement, increasing the aggregate offering amount of shares from $31 million to $50 million in connection with its at-the-market sales program. The new prospectus supplement repla

Is INNOVATE Corp a public company?

Yes. INNOVATE Corp is publicly traded under the ticker VATE.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches INNOVATE Corp across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.